An interventional study of HPV oncogenes in DNA Virus Infections, sponsored by Heba Momen kamel. Status unknown. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-15.
Sponsored by Heba Momen kamel · Not applicable, Interventional, and Basic science
Cancer is a devastating disease, presenting an immense disease burden to affected individuals and their families as well as health care systems with 10.9 million new cases and 6.7 million deaths per year. Approximately 12% of human cancers worldwide are caused by oncoviruses infection with more than 80% of cases occurring in the developing world.
Tumor viruses can be classified into two groups based on their genetic material;
DNA tumor viruses:
There are around 100 types of HPV, with different variations in their genetic and oncogenic potential [5]. Thus, HPV genotypes are divided into 2 groups based on their vulnerability; High risk HPV (HR-HPV) and low risk HPV (LR-HPV).
The HPV genome encodes several oncoproteins [5]. E6 and E7 are the main genes responsible for cell transformation mediated by HR-HPV, and they modulate the activities of cellular proteins that regulate the cell cycle. Thus, the presence of E6/E7 can be a specific marker for diagnosing precancerous lesions by HPV.
Knowledge of the etiology of virus-mediated carcinogenesis, the networking of pathways involved in the transition from infection to cancer and the risk factors associated with each type of cancer, all suggest prophylactic and therapeutic strategies that may reduce the risk of virus-mediated cancer.
Study subjects:
Inclusion criteria:
Exclusion criteria:
Study Groups:
Aim of The Study:
Studying the role of viral DNA integration in cellular transformation and carcinogenesis.
Study methods:
Samples collection and storing:
HPV detection:
HPV Genotyping:
HPV Oncogenes and oncoproteins:
Statistical analysis:
39 studies on the registry are indexed under Carcinogenesis; 10 are open to participants now.
This study's planned enrollment of 40 is below the median of 70 across 14 interventional studies indexed under Carcinogenesis.
Browse Carcinogenesis studies →Heba Momen kamel is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
HPV detection HPV Genotyping HPV Oncogenes and oncoproteins
Genetic: HPV oncogenes
HPV detection HPV Genotyping HPV Oncogenes and oncoproteins
Genetic: HPV oncogenes
PCR and oncogenes detection
carcinogenesis
developing cancer cervix
Time frame: 6 months
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
DNA Virus Infections
Heba Momen kamel